Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. (Q38089937)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23496667%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23496667%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23496667%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Matthew P Morrow

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23496667%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Jian Yan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23496667%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

1 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23496667%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Vaccines

26 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23496667%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23496667%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23496667%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

271-283

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23496667%20AND%20SRC:MED&resulttype=core&format=json

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

26 February 2020

cites work

1 reference

Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines

21 January 2018

1 reference

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

21 January 2018

1 reference

Blastocysts exhibit preferential uptake of DNA fragments from the E6-E7 conserved region of the human papillomavirus

21 January 2018

1 reference

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

The epidemiology of genital human papillomavirus infection

21 January 2018

1 reference

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

21 January 2018

1 reference

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

21 January 2018

1 reference

A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.

21 January 2018

1 reference

Virology and molecular pathogenesis of HPV (human papillomavirus)-associated oropharyngeal squamous cell carcinoma

21 January 2018

1 reference

Molecular pathogenesis of cervical cancer

21 January 2018

1 reference

Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers

21 January 2018

1 reference

A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions

21 January 2018

1 reference

The biological properties of E6 and E7 oncoproteins from human papillomaviruses.

21 January 2018

1 reference

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers

21 January 2018

1 reference

Human papillomavirus (HPV) in head and neck cancer

21 January 2018

1 reference

Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer

21 January 2018

1 reference

Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein

21 January 2018

1 reference

Detection of human papillomavirus capsid antigens in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames.

21 January 2018

1 reference

Hepatitis C virus--T-cell responses and viral escape mutations.

21 January 2018

1 reference

Buffered memory: a hypothesis for the maintenance of functional, virus-specific CD8(+) T cells during cytomegalovirus infection

21 January 2018

1 reference

Antigen-dependent and -independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection

21 January 2018

1 reference

Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers

21 January 2018

1 reference

IL-21R on T cells is critical for sustained functionality and control of chronic viral infection

21 January 2018

1 reference

IL-21 is required to control chronic viral infection

21 January 2018

1 reference

Therapeutic vaccination against human papilloma virus induced malignancies

21 January 2018

1 reference

Immunotherapy for cervical cancer: Research status and clinical potential

21 January 2018

1 reference

Therapeutic HPV DNA vaccines

21 January 2018

1 reference

The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor

21 January 2018

1 reference

Advances in the treatment of metastatic melanoma: adoptive T-cell therapy

21 January 2018

1 reference

Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors.

21 January 2018

1 reference

T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing

21 January 2018

1 reference

Cancer immunotherapy--revisited

21 January 2018

1 reference

Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2.

21 January 2018

1 reference

Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression.

21 January 2018

1 reference

HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions

21 January 2018

1 reference

Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium

21 January 2018

1 reference

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

21 January 2018

1 reference

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

21 January 2018

1 reference

Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.

21 January 2018

1 reference

Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients

21 January 2018

1 reference

HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.

21 January 2018

1 reference

Human papillomavirus and cervical cancer

21 January 2018

1 reference

Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoprotein

21 January 2018

1 reference

The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle

21 January 2018

1 reference

Therapeutic immunisation with COPV early genes by epithelial DNA delivery

21 January 2018

1 reference

Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles

21 January 2018

1 reference

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

21 January 2018

1 reference

The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis

21 January 2018

1 reference

Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques

21 January 2018

1 reference

Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer

21 January 2018

1 reference

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

21 January 2018

1 reference

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

21 January 2018

1 reference

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III

21 January 2018

1 reference

Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia

21 January 2018

1 reference

Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA.

21 January 2018

1 reference

Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control

21 January 2018

1 reference

Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles

21 January 2018

1 reference

New flow cytometric assays for monitoring cell-mediated cytotoxicity

21 January 2018

1 reference

Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses

21 January 2018

1 reference

A high-throughput single-cell analysis of human CD8⁺ T cell functions reveals discordance for cytokine secretion and cytolysis

21 January 2018

1 reference

Immunotherapy for melanoma: current status and perspectives

21 January 2018

1 reference

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.13.23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23496667%20AND%20SRC:MED&resulttype=core&format=json

release_tcigmyyzg5bepmo6nwyorfo53e

26 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tcigmyyzg5bepmo6nwyorfo53e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference